The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TRVN, CWH, HON, OZK and ATUS

NEW YORK, Dec. 05, 2018 (GLOBE NEWSWIRE) — The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Trevena, Inc. (NASDAQGS: TRVN)
Class Period: May 2, 2016 to October 9, 2018
Lead Plaintiff Deadline: December 10, 2018

According to the complaint, Trevena, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (a) during its meetings with the FDA prior to the start of the Class Period, Trevena had been advised that the FDA did not agree with certain aspects of the design of the Phase III clinical trial of Olinvo, including the proposed dosing, the proposed primary endpoint and the proposed non-inferiority margin for comparing morphine to Olinvo; (b) unless Trevena demonstrated that Olinvo was at least equally effective to morphine in treating post-operative pain in the Phase III clinical trial, the FDA would be unwilling to consider any secondary benefits Olinvo might confer in terms of reduced opioid-related adverse effects (“ORAEs”); (c) the FDA disagreed with how the safety data was being compiled in the Phase II clinical trial; (d) because the FDA did not agree with major tenants of the design of the Phase III clinical trial, it was highly unlikely that the FDA would find the data obtained from that clinical trial sufficient to support Trevena’s NDA; (e) because the Phase III clinical trial data being derived would not likely be deemed sufficient to support the NDA for Olinvo, the Company would not be able to market Olinvo as soon as it was leading the market to expect, if ever; and (f) as a result of the foregoing, the Company was not on track to achieve the commercial sales revenues from Olinvo as soon as Defendants had led the market to expect during the Class Period, if ever.

Get additional information about the TRVN lawsuit: http://www.kleinstocklaw.com/pslra-1/trevena-inc-loss-submission-form?wire=3

Camping World Holdings, Inc. (NYSE: CWH)
Class Period: March 8, 2017 to August 7, 2018
Lead Plaintiff Deadline: December 18, 2018

Camping World Holdings, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company’s disclosure controls and controls over financial reporting suffered from a host of material weaknesses; (2) the Company’s historical financial results had been materially misstated; (3) the Gander stores had encountered integration setbacks, adversely impacting the Company’s earnings growth and profit margins; and (4) the Company’s core RV business was experiencing decelerating growth as the Company lagged industry trends and was losing market share to competitors.

Get additional information about the CWH lawsuit: http://www.kleinstocklaw.com/pslra-1/camping-world-holdings-inc-loss-submission-form?wire=3

Honeywell International Inc. (NYSE: HON)
Class Period: February 9, 2018 to October 19, 2018
Lead Plaintiff Deadline: December 31, 2018

According to the complaint, Honeywell International Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Honeywell’s Bendix Friction Materials (“Bendix”) asbestos-related liability was greater than initially reported; (2) the Company maintained improper accounting practices in connection with its Bendix asbestos-related liability; and (3) as a result, Honeywell’s public statements were materially false and misleading at all relevant times. 

Honeywell previously owned Bendix, which used asbestos in its brake- and clutch-pad products until 2001; the Company sold Bendix in 2014. On August 23, 2018, Honeywell announced it had “revised its method for reasonably estimating its liability for unasserted Bendix asbestos-related claims by considering the epidemiological projections through 2059 of future incidence of Bendix asbestos-related disease. Using this method, the Company’s Bendix asbestos-related liability is estimated to be $1,693 million as of June 30, 2018. This is $1,083 million higher than the Company’s prior estimation which applied a five-year horizon when estimating the liability for unasserted Bendix asbestos-related claims. The Bendix asbestos-related insurance assets are estimated to be $187 million as of June 30, 2018, which is $65 million higher than the Company’s prior estimate.”

Get additional information about the HON lawsuit: http://www.kleinstocklaw.com/pslra-1/honeywell-international-inc-loss-submission-form?wire=3

Bank OZK (NASDAQGS: OZK)
Class Period: February 19, 2016 to October 18, 2018
Lead Plaintiff Deadline: December 26, 2018

The complaint alleges that throughout the class period Bank OZK made materially false and/or misleading statements and/or failed to disclose that: (1) the Company lacked adequate internal controls to assess credit risk; (2) as a result, certain of the Company’s loans posed an increased risk of loss; (3) certain substandard loans were reasonably likely to lead to charge-offs; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.   On October 18, 2018, the Company reported that it had “incurred combined charge-offs of $45.5 million on two Real Estate Specialties Group credits” that had previously been classified as substandard. On this news, the Company’s share price fell $9.33 per share to close at $25.52 per share on October 19, 2018.

Get additional information about the OZK lawsuit: http://www.kleinstocklaw.com/pslra-1/bank-ozk-loss-submission-form?wire=3

Altice USA, Inc. (NYSE: ATUS)
Class Period: Pursuant and/or traceable to the June 2017 Initial Public Offering
Lead Plaintiff Deadline: January 18, 2019

The complaint alleges that the Offering Documents issued pursuant to the IPO failed to disclose and/or misstated material information, including that: (1) “The Altice Way” proprietary growth model previously developed in Europe and described in the Offering Documents as a means to achieve superior margin performance was falsely touting Altice’s capacity to face already existing highly competitive environments and ever-changing consumer behaviors; (2) Altice was suffering from aggressively growing competition both in Europe and the United States, directly causing negative and decelerating revenue and EBITDA growth and impacting Altice’s market share; (3) specifically, Altice was suffering from mismanaged rate events, regulatory compliance and poorly managed network and customer care both in its France and Portugal segments, thereby impacting its customer base and churn rate; (4) Altice USA could not simply replicate the “The Altice Way” in the U.S.; and (5) as a result, Altice USA’s Offering Documents were materially misleading at all relevant times. 

Get additional information about the ATUS lawsuit: http://www.kleinstocklaw.com/pslra-1/altice-usa-inc-atus-loss-submission-form?wire=3

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

Share this post